Language
English
Publication Date
9-1-2024
Journal
Pediatric Blood & Cancer
DOI
10.1002/pbc.31169
PMID
38961583
PMCID
PMC11514057
PubMedCentral® Posted Date
9-1-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Methotrexate is a critical component of curative chemotherapy for pediatric acute lymphoblastic leukemia (ALL), but is associated with neurotoxicity. Information on long-term outcomes following an acute neurotoxic event is limited. Therefore, this report compares neurocognitive performance more than 12 months post diagnosis (mean = 4 years) between ALL patients with (n = 25) and without (n = 146) a history of acute neurotoxicity. Compared to children with no documented on-treatment neurotoxic event, children who experienced a neurotoxic event during treatment exhibited poorer performance on measures of fine motor function (p = .02) and attention (p = .02). Children with ALL who experience acute neurotoxicity may be candidates for early neuropsychological screening and intervention.
Keywords
Humans, Methotrexate, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Female, Male, Neurotoxicity Syndromes, Child, Child, Preschool, Antimetabolites, Antineoplastic, Adolescent, Follow-Up Studies, Neuropsychological Tests, Prognosis, methotrexate, toxicity, late-effects, leukemia, psychology, neurocognition
Published Open-Access
yes
Recommended Citation
Harris, Rachel D; Taylor, Olga A; Raghubar, Kimberly P; et al., "Episodes of Acute Methotrexate-Related Neurotoxicity Linked to Compromised Long-Term Neurocognitive Function" (2024). Faculty and Staff Publications. 5916.
https://digitalcommons.library.tmc.edu/baylor_docs/5916